Bosch-Boonstra-Schaaf optic atrophy syndrome
Bosch-Boonstra-Schaaf optic atrophy syndrome (BBSOAS) is a rare genetic disorder characterized by a variety of symptoms, most notably optic atrophy and intellectual disability. The syndrome was first described by Bosch, Boonstra, and Schaaf in 2014.
Symptoms and Signs[edit | edit source]
The primary symptom of BBSOAS is optic atrophy, a condition that leads to the degeneration of the optic nerves, resulting in vision loss. Other symptoms can include intellectual disability, developmental delay, and behavioral abnormalities. Some individuals with BOSOAS may also have seizures, muscle weakness, and abnormalities in brain structure.
Genetics[edit | edit source]
BBSOAS is caused by mutations in the NR2F1 gene. This gene provides instructions for making a protein that is involved in the development of the brain and eyes. The mutations that cause BBSOAS result in a reduction or absence of this protein, which disrupts normal development and leads to the symptoms of the syndrome.
Diagnosis[edit | edit source]
Diagnosis of BBSOAS is based on clinical features and confirmed by genetic testing. Magnetic resonance imaging (MRI) may also be used to identify abnormalities in brain structure.
Treatment[edit | edit source]
There is currently no cure for BBSOAS. Treatment is symptomatic and supportive, and may include physical therapy, special education, and medications to manage seizures.
Prognosis[edit | edit source]
The prognosis for individuals with BBSOAS varies. Some individuals may have mild symptoms and live independently, while others may require lifelong care.
See also[edit | edit source]
References[edit | edit source]
- Bosch, D. G., Boonstra, F. N., de Leeuw, N., Pfundt, R., Nillesen, W. M., de Ligt, J., ... & de Vries, B. B. (2014). Novel genetic causes for cerebral visual impairment. European journal of human genetics, 24(5), 660-665.
Bosch-Boonstra-Schaaf optic atrophy syndrome Resources | |
---|---|
|
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD